Are UTZ, VEEE, CRNX Obtaining Fair Deals for their Shareholders?

Halper Sadeh LLC says it is investigating potential federal securities-law violations and fiduciary-duty breaches tied to multiple transactions, including Utz Brands’ sale to Intersnack for $14.25/share and Crinetics Pharmaceuticals’ sale to Vertex for $85.00/share, plus Twin Vee PowerCats’ merger with USFM. The firm indicates it may seek increased consideration, additional disclosures, or other relief for shareholders, which adds regulatory/legal overhang to the deal processes.

Analysis

This is a spread-and-timing event, not a fundamental reset. The main impact is to nudge up closing uncertainty and legal carry costs, which tends to matter more for smaller, less-liquid names where arbitrage capital is thinner and passive holders are quicker to de-risk. The economic transfer is mostly from common holders to the event-driven ecosystem unless the process challenge uncovers real disclosure or fiduciary defects.

CRNX is the cleanest relative-value setup because the buyer profile is strategic and the deal should be less sensitive to financing markets; any widening in the implied spread is more likely to be time value than a true break signal. UTZ should be the steadiest if the buyer has no obvious antitrust overlap, but consumer M&A often attracts nuisance litigation that can shave quarterly IRR for arb funds without changing ultimate value. VEEE is the fragile one: microcap mergers with limited liquidity can see outsized markdowns on even low-grade legal noise, and that can become self-fulfilling if holders start voting with their feet.

The contrarian view is that these notices are usually low-signal until a real injunction, supplemental disclosure request, or price revision appears. The market often overpays for headline risk and underprices the probability that the case resolves as a fee transfer rather than a deal failure. Falsifiers are straightforward: a court process that delays closing by more than one quarter, a dropped vote, or any buyer-side renegotiation. Absent that, the better trade is often to fade spread blowouts rather than short the targets outright.

Key Decisions for Investors

• Buy CRNX and UTZ only if the implied deal spread widens materially versus current marks; target a low-teens annualized IRR into expected close, and exit if the spread does not compress after the next filing cycle.
• No fresh position in VEEE until there is clarity on voting support, financing, and any plaintiff demand; microcap merger noise can create false breaks, so treat it as a watch item, not a conviction short.
• For event-driven books, consider a merger-arb basket long CRNX/UTZ versus cash or a broad healthcare/consumer basket to isolate deal-specific spread rather than beta.
• Set a hard risk trigger: abandon the arb thesis if there is a preliminary injunction, amended consideration, or a formal competing bid; those are the events that change the payoff, not the law-firm notice itself.